与先进的非小细胞肺癌中的第一线布利祖马布同时使用的药物和生存率
Adrien Rousseau1,2, Noémie Simon-Tillaux2,3, Stefan Michiels2,3
1Department of Cancer Medicine, Gustave Roussy, Thoracic Group and International Center for Thoracic Cancers, Paris-Saclay University, Villejuif, France.
JAMA network open
|September 10, 2025
概括
某些抗生素,类固醇和质子抑制剂 (PPI) 可能会降低免疫治疗在高级非小细胞肺癌 (NSCLC) 患者的有效性. 仔细监测这些疗法对于优化整体生存 (OS) 结果至关重要.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 免疫疗法,特别是 pembrolizumab,已经彻底改变了高级非小细胞肺癌 (NSCLC) 治疗.
- 然而,同时服用药物的对免疫治疗疗效的影响仍然是研究的关键领域.
- 抗生素,类固醇和质子抑制剂 (PPI) 经常用于癌症患者,并被怀疑会干扰免疫检查点抑制剂.
研究的目的:
- 在接受一线 pembrolizumab治疗的晚期NSCLC 患者中,研究药物治疗 (抗生素,类固醇,PPI) 与整体存活率 (OS) 之间的关联.
- 为了确定这些药物的特定类别或剂量是否会影响治疗结果.
主要方法:
- 一项全国性的回顾性队列研究,使用2015年1月至2022年12月的法国国家医疗保健数据.
- 目标试验模拟包括先进的NSCLC患者,接受一线 pembrolizumab 治疗,在开始后2个月活着.
- 使用治疗权重的逆概率 (IPTW) 来调整暴露和未暴露组之间的混因素.
主要成果:
- 抗生素暴露 (不包括宏类药物和青素) 与较短的生存期有关 (HR,1.08).
- 类固醇使用与整体的OS没有显著的关联 (HR,0.98),但在较高剂量 (>20mg的普雷尼松等效单独用于pembrolizumab,>30mg用于pembrolizumab加化疗) 时观察到剂量依赖的负面影响.
- 质子抑制剂 (PPI) 暴露显著与更糟糕的OS相关 (HR,1.13).
结论:
- 与某些抗生素,高剂量类固醇和PPI的联合治疗与用 pembrolizumab治疗的晚期NSCLC患者的整体存活率较差有关.
- 这些发现强调了在接受免疫治疗的患者中仔细考虑和监测共用药物的重要性.
- 对这些药物相互作用的机制和最佳管理策略的进一步研究是有必要的.
更多相关视频
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
10.9K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.9K
相关概念视频
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
01:21Cancer Survival Analysis
624
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
624